Due to aberrantly high levels of LPA and overexpression of LPAR1 in IPF patients, LPAR1 inhibitor such as BMS-986020 have also been evaluated in clinical trials for the treatment of IPF [39,40]. This evidence concerns the gene LPAR1 and idiopathic pulmonary fibrosis.